HLB bioStep: Sharp Share Price Rebound Meets Continued Operating Losses

Thesis

The data supports a picture of a small KOSDAQ biotech services company whose revenue has recovered since 2023 but which has not returned to profit. Revenue grew 27.3% in 2025 and the operating margin improved from -22.3% in 2024 to -11.6% in 2025, and further to -8.7% on a trailing basis. Net losses, however, widened to ₩19.0B in 2025 and remain at ₩18.4B on a trailing basis, so the improvement at the operating level has not reached the bottom line. The recent price surge is not explained by anything in the filings shown. News on 2026-10-13 reports participation in a ₩5B national AI research project, but the data does not give the company's share of that amount or any revenue effect. Over the last 20 days retail investors were net buyers while foreign investors were net sellers, and foreign ownership fell from 1.1% to 0.3% over 60 days.

Business overview

HLB bioStep is listed on KOSDAQ in the Biotech & Pharma sector. It was founded on 2012-04-19 and listed on 2019-11-27, with 17,432,396 listed shares and a market capitalization of about ₩92.2B. Revenue was ₩64.4B in 2021, peaked at ₩86.3B in 2022, fell 38.8% to ₩52.8B in 2023, then recovered to ₩58.2B in 2024 and ₩74.1B in 2025. The company was profitable at the operating level in 2021 and 2022 (margins of 15.3% and 7.4%) but has been loss-making at that level since 2023. A news headline describes a push to become a 'Digital Non-Clinical CRO', but the data gives no further detail on the business mix.

Financial analysis

These figures come from filed financial statements. On a trailing basis to H1 2026, revenue was ₩72.2B, operating income was -₩6.3B (margin -8.7%), net income was -₩18.4B (margin -25.5%) and ROE was -18.1%. Annual net income was ₩11.0B in 2021, -₩3.0B in 2022, -₩0.2B in 2023, -₩8.6B in 2024 and -₩19.0B in 2025. The balance sheet shows cash of ₩33.3B against borrowings of ₩29.4B, and liabilities to equity of 50.9%. Trailing free cash flow was -₩2.5B, so the company is still consuming a modest amount of cash. Filings in July and September 2026 show decisions on acquiring its own convertible bonds before maturity, though the data does not give the amounts.

Valuation

On current figures the price-to-book ratio is 1.0 and the price-to-sales ratio is 1.3, with enterprise value of about ₩88.3B. Price-to-earnings and EV/EBITDA cannot be calculated because earnings are negative, and the dividend yield is 0.0%. Year-end price-to-book was 4.3 in 2021, 5.9 in 2022, 2.7 in 2023, 1.6 in 2024 and 1.3 in 2025, so the current 1.0 is below the company's own recent history. The listed peers are much larger companies: price-to-book ranges from 2.5 (Celltrion, Yuhan) to 30.4 (Alteogen), and price-to-earnings from 14.3 to 84.4, so the comparison has limited relevance. A valuation model estimate per share is not available for this company because it could not be worked out from the data. The 52-week low in the data is shown as ₩0 and should be treated as unreliable.

Catalysts

• The 2026-10-13 news that the company joined a ₩5B national AI-NAMs research project could matter if it leads to revenue, though the data does not quantify its share.
• An investor relations event was filed on 2026-10-12, which may bring more detail on strategy and results.
• A 5%+ holding report was filed on 2026-10-13, showing a change in a major shareholder's stake, though the data does not say in which direction.
• Repeated filings on early acquisition of own convertible bonds (July and September 2026) could change the company's debt and share structure.
• The next periodic filing will show whether the trailing operating loss of ₩6.3B continues to narrow.

Risks

• Net losses have persisted and widened since 2023, with a trailing net margin of -25.5% and ROE of -18.1%.
• The share price rose 111.6% in a month, and a move of that size can reverse, as the 1-year return is still -20.0%.
• Free cash flow is negative at -₩2.5B, and borrowings of ₩29.4B are close to cash of ₩33.3B.
• Foreign ownership has fallen to 0.3% and 20-day foreign flows are net negative, while retail investors dominate buying, which can mean volatile trading.
• Revenue has been uneven, with a 38.8% fall in 2023, and the data gives no company guidance or order information.

Closing view

The data shows a company whose sales and operating margin have been improving but which is still unprofitable, with losses that grew at the net level. The share price has rebounded sharply and the price-to-book ratio of 1.0 is below its own recent history, yet no model estimate is available and the filings shown do not explain the rally. Balance sheet leverage is moderate and cash roughly covers borrowings. Investors would need to watch whether operating losses close and whether new projects translate into revenue, as the data does not settle either question.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Filings and data used

• 5%+ holding reportOct 13, 2026
• Investor relations (IR) eventOct 12, 2026
• Material Matters Report (Decision on Acquisition of Own Convertible Bonds Before Maturity)Sep 3, 2026
• 5%+ holding reportAug 28, 2026
• Insider shareholding reportAug 27, 2026
• Half-year report (Jun 2026)Aug 14, 2026
• 5%+ holding reportJul 22, 2026
• Material Matters Report (Decision on Acquisition of Own Convertible Bonds Before Maturity)Jul 21, 2026
• Insider shareholding reportJul 21, 2026
• Material Matters Report (Decision on Acquisition of Own Convertible Bonds Before Maturity)Jul 14, 2026
• Insider shareholding reportJul 1, 2026
• Non-designation as Unfaithful Disclosure Company (Reversal of Disclosure)Jun 23, 2026
• HLB Biostep Joins ₩5B National AI-NAMs Research Project, Targets Position as 'Digital Non-Clinical CRO'Oct 13, 2026
• Daily prices up to 2026-10-16
• Financial statements, trailing 12 months as of H1 2026

Report history

1. Oct 18, 2026InitiationStart of coverage (reader request)HLB bioStep: Sharp Share Price Rebound Meets Continued Operating Losses